Medspa revenue grew 17.4% in Q3 2026. New patient counts stayed flat.

Who this is for

This is for the physician or medical professional who owns a medspa or an aesthetic practice with an injectables line, and/or the operations lead who decides how the budget and the front desk's hours are split between finding new patients and keeping the ones already on the books.

That split comes up every time a marketing contract renews. Money for new patient acquisition and money for medspa patient retention come out of the same budget, and most practices have no clean way to price one against the other.

CorralData sells reporting software to aesthetics operators.¹ It published a benchmark for the third quarter of 2026 (Q3), and Modern Aesthetics reported the main numbers in a 2026 news piece.² The data points are vendor-published and cover the most recent full quarter.

Where did the 17.4% growth come from, if new patient counts stayed flat?

Most of the growth came from patients who had been in before and from locations that were still new. Median revenue across CorralData's medspa locations rose 17.4% in Q3 2026 against Q3 2025, a rise the report describes as "driven largely by existing patients and newer locations."²

Existing patients produced about 82% of revenue in the quarter, and revenue from that group grew 8.4% year on year. The three growth data points sit on different bases: 17.4% is the change in median revenue per location, 7.0% is the change at locations open two years or more, and 8.4% is the change in what existing patients spent. The gaps between them are not a calculation. Modern Aesthetics does not say how recently a patient must have visited to count as existing. New patient counts stayed close to flat, and the revenue new patients brought in went down.²

Modern Aesthetics gives no reason for the fall in new-patient revenue.²

According to Modern Aesthetics, the benchmark draws on operator systems data, with no survey answers in it.²

An established practice should not set its own growth against the 17.4% directly. That data point is a median across all locations, including young ones still filling their schedules. Among locations open at least two years, which the report calls same-store, revenue rose 7.0%.²

For a practice that has been open a few years, 7.0% is the closer comparison. Our reading of the gap between 17.4% and 7.0% is that newer locations grow the way any new business does, by booking people who have never visited. Modern Aesthetics gives no split of the newer locations' revenue by patient type.²

A good part of what a firm like ours is hired for helps a practice get found by someone who has never booked there. In this data, revenue from that group is whatever sits outside existing patients' 82%, and Modern Aesthetics gives no separate share for it.²

CorralData's data points show where revenue came from in one quarter. They do not project how a practice's book of patients changes over several years.

How often did Q3 2026 medspa patients come back, and who spent the most?

Members came back at close to twice the rate of nonmembers. During the quarter, 90.4% of members returned, against 50.6% of nonmembers.² Modern Aesthetics does not say what counted as a return.

That gap has a selection problem. Patients who already plan to come back are the likeliest to join a membership, so some share of the 90.4% would have returned without one. Modern Aesthetics describes no comparison that separates the effect of the membership from the habits of the people who signed up.²

Modern Aesthetics gives membership enrollment as a range across operators.² A membership changes how a patient pays and how often the practice sees them. It also commits the practice to a monthly service level, and that commitment sits with the staff who run the schedule.

Rebooking was common: 71.0% of completed appointments led to another booking within 90 days.² That rate counts appointments. A patient with four visits a year counts four times, so a group of frequent patients can lift it while many occasional patients drift away.

Spending was concentrated. The highest-spending 10% of patients accounted for 35.5% of revenue.²

Average patient lifetime revenue was $1,628.² Patient lifetime value usually means the revenue one patient brings a practice across the whole relationship. Modern Aesthetics reports the data point from CorralData's operator data and gives no time window, no region and no median for it. No other source here reports a lifetime data point, so the article sets it against nothing.

With a tenth of patients producing 35.5% of revenue, the average is pulled toward the top spenders, and the typical patient's lifetime revenue may sit below $1,628. A practice's own median, from its own records, sits on the same basis as its own book.

This concentration is a patient mix question for the owner. When a small group carries a third of revenue, losing a handful of those patients would show up in the monthly numbers within a quarter or two. Who those patients are, which provider they see, and what they come in for are facts the front desk and the injectors usually know before the owner does.

Do AmSpa, Zenoti and BCG point the same way?

They point the same way, and each counts something different. Zenoti sells booking and business software to salons, spas and medspas. Its 2025 benchmark report, covering 2024, states that "42% of loyal clients (those visiting more than once a year) drive 80% of total revenue."³

Zenoti's data mixes medspas with salons and waxing businesses, so it describes beauty and wellness broadly. The same report says salons, medspas and waxing businesses averaged 24% membership sales growth in 2024.³

The two rows differ in definition, year and business type. CorralData counts any existing patient at medspas in one quarter of 2026. Zenoti counts clients who visited more than once in 2024, across salons, spas and medspas. Read together, they show only that both land near 80%; neither row is a trend line for the other.^2,3

The American Med Spa Association (AmSpa) is a trade association whose members are medspa owners. In its 2024 State of the Industry survey, 73% of medspa patients were repeat patients on average, up from 65% in AmSpa's 2022 report.^4,5 The recap reports the share as owners gave it, with no visit threshold stated like Zenoti's "more than once a year."

AmSpa's 73% is a share of patients, reported by owners. CorralData's 82% is a share of revenue, taken from software records. Both can hold at the same time.^2,4

AmSpa's recap does not say the same medspas answered both rounds, so the 65% and the 73% are two snapshots from separate surveys.^4,5

The same AmSpa survey put average annual revenue per medspa at $1,398,833, up from $1,307,587 in AmSpa's previous report.⁴ Both are owners' reports of a full year's revenue, averaged across the medspas that answered each round, and the recap does not say the same medspas answered both. They sit on a different basis from CorralData's 17.4%, which is the change in median revenue across one vendor's locations in a single quarter, so the two growth rates cannot be compared.

Boston Consulting Group's 2024 report on medical aesthetics consumers comes from the patient side. BCG surveyed 5,000 consumers in ten countries, including the US, Brazil and China. 85% planned to spend the same amount or more on procedures in the coming year: 50% planned to spend more and 35% to keep spending level.⁶

BCG's 2025 report put the share planning to maintain or raise spending at 93%, with 94% among millennials and 87% among Gen Z respondents.⁷ BCG's 2025 report charts the two itself as an eight-point rise.⁷ The passages we read do not say whether both rounds asked the same countries the same question, so that rise rests on BCG's own comparison, which we could not check.

Both BCG reports record what people say they will spend. The 8.4% growth in existing-patient revenue in CorralData's data records payments.^2,6,7

BCG's 2024 report sorts these consumers into six types, including people who get two or more medical aesthetics treatments a year.⁶

Every medspa revenue data point cited here comes from a vendor or a trade association.

What does published research tie to aesthetic patients coming back?

The journal record is thin. A 2021 multicenter retrospective review in the Journal of Cosmetic Dermatology examined patient retention across 7 aesthetic practices after neuromodulator and hyaluronic acid filler treatment.⁸

A retrospective review cannot separate cause from selection. Patients who were already inclined to stay may also have been the patients offered more treatment, and records alone do not tell the two apart.

A 2021 commentary in Aesthetic Surgery Journal states that about 40% of cosmetic surgery patients and about 60% of patients who have minimally invasive procedures are repeat patients.⁹ The commentary cites the data points to a footnote and shows none of the underlying data, so they carry less weight than a study would.

The commentary's 40% and 60% are shares of patients, from 2021. CorralData's 82% is a share of medspa revenue in 2026, and the Q3 report as published says nothing about surgical practices.^2,9

None of these sources publishes a new patient acquisition cost for medspas. Without that number, the comparison owners most want, what a new patient costs to win against what an existing patient costs to keep, cannot be made from public data.

Which of CorralData's measures can a practice find in its own records?

Three of CorralData's numbers have a counterpart in a practice's scheduling and payment software: the share of revenue from returning patients, the share of completed appointments rebooked within 90 days, and the share of revenue from the top tenth of patients.²

CorralData's operators are a sample of its own customers. A practice's change from one year to the next compares the practice with itself, while its distance from the benchmark compares it with those customers, who may work in different markets.

Whether new-patient marketing pays back turns on two numbers: what a new patient costs to win and what that patient spends in the first year. Both sit in a practice's own books, and none of the public sources here publishes them for medspas.

About this review

In October 2026 we read the Modern Aesthetics report on CorralData's Q3 2026 benchmark, CorralData's reporting page, Zenoti's 2025 benchmark, AmSpa's 2024 survey recap and its earlier article on repeat patients, BCG's 2024 and 2025 medical aesthetics reports, and the 2021 Aesthetic Surgery Journal commentary. [S1 to S5, S7 to S9] The Journal of Cosmetic Dermatology study was read in its abstract, which as available to us ended before its results, so no retention data points from it are reported here.⁸

CorralData's page does not say how many locations the benchmark covers or how they were chosen. Its data comes from operators who use its software. That group may differ from medspas in general, and locations that closed during the year drop out of any same-store data point. Zenoti publishes no sample size or selection method. AmSpa is a trade association with a commercial interest in the industry's health. BCG's data points are stated spending intentions, gathered across ten countries. AmSpa surveys medspas in the US. The passages we read from CorralData and Zenoti do not say which countries their locations are in.

Fractional Aesthetics is a growth strategy practice for aesthetic medical businesses.